Company Profile
PharmaNutra S.p.A. specializes in the research, development and marketing of nutraceutical products. Also, the group develops an activity involving the manufacturing and sales of medical devices and pharmaceuticals. The group's activity is organized around 3 product families:
- food supplements: iron, folic acids, vitamins, omega 3 and microelement-based products sold under SiderAL, Gestalys, Bonecal, Novomega and Dikappa2 brands, intended for the treatment of anemia and food deficit, and the prevention of cardiovascular disorders. Additionally, PharmaNutra S.p.A. offers anti-inflammatory products for joint and musculoskeletal pain relief (Cetilar);
- medical devices, generic drugs and OTC products (Junia Pharma). Moreover, the group markets infant nutritional supplements;
- bioactive ingredients and pharmaceutical active ingredients (Alesco): for the pharmaceutical, agri-food and nutraceutical industries.
Its products are marketed through direct sales (63.4% of net sales), partner distributors (31.6%) and other (5%).
Net sales are distributed geographically as follows: Italy (67.8%), Europe (16.9%), Middle East (10.6%), South America (1.9%), Far East (1.5%) and other (1.3%).
- food supplements: iron, folic acids, vitamins, omega 3 and microelement-based products sold under SiderAL, Gestalys, Bonecal, Novomega and Dikappa2 brands, intended for the treatment of anemia and food deficit, and the prevention of cardiovascular disorders. Additionally, PharmaNutra S.p.A. offers anti-inflammatory products for joint and musculoskeletal pain relief (Cetilar);
- medical devices, generic drugs and OTC products (Junia Pharma). Moreover, the group markets infant nutritional supplements;
- bioactive ingredients and pharmaceutical active ingredients (Alesco): for the pharmaceutical, agri-food and nutraceutical industries.
Its products are marketed through direct sales (63.4% of net sales), partner distributors (31.6%) and other (5%).
Net sales are distributed geographically as follows: Italy (67.8%), Europe (16.9%), Middle East (10.6%), South America (1.9%), Far East (1.5%) and other (1.3%).
Source: Cofisem - Last Update: 2024-09-17
Key Executives
| Chairman and Chief Executive Officer | |
| Chief Executive Officer | |
| Chief Operating Officer |
Source: Cofisem - Last Update: 2024-09-17
Key Figures
| Millenium | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Net sales | 100,202 | 82,724 | 68,114 | 56,449 | 53,624 |
| Income from ordinary activities | 100,202 | 82,724 | 68,114 | 56,449 | 53,624 |
| Operating income | 23,360 | 23,040 | 18,691 | 13,216 | 12,204 |
| Cost of financial indebtedness net | 482 | -68 | -99 | -61 | -28 |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income | 12,832 | 15,048 | 13,771 | 14,072 | 8,454 |
| Net income (Group share) | 12,832 | 15,048 | 13,771 | 14,072 | 8,454 |
| Fiscal year end | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
Source: Cofisem - Last Update: 2024-09-17
Shareholder information
| Andrea Lacorte | |
| Roberto Lacorte | |
| Azimut Libera Impresa SGR SpA | |
| Beda S.r.l. | |
| Norges Bank | |
| Rlh S.r.l. |
Source: Cofisem - Last Update: 2024-09-17
Address
PharmaNutra S.p.A.
Via Campodavela 1
IT-56122 Pisa
Italy
Phone number: +39 050 7846500
Fax: +39 050 7846524
https://www.pharmanutra.it/it/
Source: Cofisem - Last Update: 2024-09-17
Contact
Francesco Sarti
Phone number: +390507846500
f.sarti@pharmanutra.it
Phone number: +390507846500
f.sarti@pharmanutra.it
Source: PharmaNutra S.p.A. - Last Update: 2024-09-17
Please contact MyQuestion.Italy@euronext.com for Company Profile support.